These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34177704)

  • 1. Enhancing the Self: Amateur Bodybuilders Making Sense of Experiences With Appearance and Performance-Enhancing Drugs.
    Macho J; Mudrak J; Slepicka P
    Front Psychol; 2021; 12():648467. PubMed ID: 34177704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Appearance- and Performance-Enhancing Drugs on Personality Traits.
    Zaami S; Minutillo A; Sirignano A; Marinelli E
    Front Psychiatry; 2021; 12():730167. PubMed ID: 34630182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Paths to Appearance- and Performance-Enhancing Drug Use in Bodybuilding.
    Coquet R; Roussel P; Ohl F
    Front Psychol; 2018; 9():1431. PubMed ID: 30135676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-enhancing drugs on the web: a growing public-health issue.
    Brennan BP; Kanayama G; Pope HG
    Am J Addict; 2013; 22(2):158-61. PubMed ID: 23414502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance and Performance-Enhancing Drugs and Supplements, Eating Disorders Symptoms, Drive for Muscularity, and Sexual Orientation in a Sample of Young Men.
    Ghaderi A; Welch E
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional Effects of Appearance and Performance Enhancing Drugs (APEDs) Use on Mood in Powerlifters and Bodybuilders.
    Sanjuan PM; Pearson MR; Langenbucher JL
    Alcohol Treat Q; 2015; 33(4):444-457. PubMed ID: 27182105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Legal Appearance- and Performance-Enhancing Drugs and Substances: Findings from the Canadian Study of Adolescent Health Behaviors.
    Ganson KT; Hallward L; Cunningham ML; Murray SB; Nagata JM
    Subst Use Misuse; 2023; 58(2):289-297. PubMed ID: 36576273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Prevalence of Psychiatric Disorders in Performance-Enhancing Drug Users and Nonuser Bodybuilders.
    Ostovar A; Haerinejad MJ; Akbarzadeh S; Keshavarz M
    Iran J Psychiatry; 2017 Oct; 12(4):223-228. PubMed ID: 29472947
    [No Abstract]   [Full Text] [Related]  

  • 9. The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs.
    Albertson TE; Chenoweth JA; Colby DK; Sutter ME
    FP Essent; 2016 Feb; 441():30-43. PubMed ID: 26881771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the social lives of image and performance enhancing drugs: An online ethnography of the Zyzz fandom of recreational bodybuilders.
    Underwood M
    Int J Drug Policy; 2017 Jan; 39():78-85. PubMed ID: 27768997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is competitive body-building pathological? Survey of 984 male strength trainers.
    Steele I; Pope H; Ip EJ; Barnett MJ; Kanayama G
    BMJ Open Sport Exerc Med; 2020; 6(1):e000708. PubMed ID: 32419952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling population heterogeneity in appearance- and performance-enhancing drug (APED) use: applications of mixture modeling in 400 regular APED users.
    Hildebrandt T; Langenbucher JW; Carr SJ; Sanjuan P
    J Abnorm Psychol; 2007 Nov; 116(4):717-33. PubMed ID: 18020718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining and defending drug-free bodybuilding: A current perspective from organisations and their key figures.
    Liokaftos D
    Int J Drug Policy; 2018 Oct; 60():47-55. PubMed ID: 30099331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerable discipline: experiences of male competitive bodybuilders.
    Bjørnestad J; Kandal Ø; Anderssen N
    J Health Psychol; 2014 Sep; 19(9):1174-84. PubMed ID: 23682065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisioning, reconnecting and revisiting: the psychosocial transition of returning home from hospital following a stroke.
    Pringle J; Drummond JS; McLafferty E
    Disabil Rehabil; 2013; 35(23):1991-9. PubMed ID: 23614358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social suppliers: Exploring the cultural contours of the performance and image enhancing drug (PIED) market among bodybuilders in the Netherlands and Belgium.
    van de Ven K; Mulrooney KJ
    Int J Drug Policy; 2017 Feb; 40():6-15. PubMed ID: 27574781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and correlates of appearance- and performance-enhancing drugs and substances use among a national sample of college students aged 18-30.
    Ganson KT; Nagata JM
    J Am Coll Health; 2024 Jul; 72(5):1336-1340. PubMed ID: 35623043
    [No Abstract]   [Full Text] [Related]  

  • 18. Competitive Bodybuilding: Fitness, Pathology, or Both?
    Steele IH; Pope HG; Kanayama G
    Harv Rev Psychiatry; 2019; 27(4):233-240. PubMed ID: 31219882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the recovery of a sense of self: An interpretative phenomenological analysis of patients' experience of body-oriented psychotherapy for schizophrenia.
    Galbusera L; Fellin L; Fuchs T
    Psychother Res; 2019 Feb; 29(2):234-250. PubMed ID: 28532254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids.
    Smit DL; de Hon O; Venhuis BJ; den Heijer M; de Ronde W
    Scand J Med Sci Sports; 2020 Mar; 30(3):531-539. PubMed ID: 31663164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.